Moebius leverages its proprietary liposomal technologies and related expertise in the development of novel products for unmet medical needs.

About Us

Moebius Medical is an innovative clinical-stage biotech company that leverages its proprietary liposomal technologies and related expertise in the development of novel products.
We were founded in 2008 within the RAD Biomed Accelerator to commercialize a patent-protected liposomal technology licensed from the Hebrew University of Jerusalem, the Technion Institute and Hadassah Medical Center.

Learn More

Meet our Team

At Moebius, people are everything. Moebius’s scientific team, which drives our business, bring years of experience and leadership in liposome technology, process development, analytics, and CMC (Chemistry, Manufacturing & Controls), which is complemented by a deep understanding of joint lubrication and cartilage regeneration. On the business side, our leadership brings years of experience in pharmaceutical and medical device business development, marketing and sales.

LEARN MORE

Our Lead Product

Moebius’s lead product, MM-II, is a novel non-opioid intra-articular injection that leverages the physical properties of proprietary multilamellar liposomes and an innovative mechanism-of-action to provide sustainable relief of symptomatic knee pain in osteoarthritic patients.

LEARN MORE

News & Press Releases

Clinical Trials

We are currently recruiting patients with symptomatic knee osteoarthritis to participate in a large clinical trial to be carried out in the US, Denmark and Hong Kong.

More information

Partnering

Moebius is interested in leveraging its experience and expertise in the development of additional innovative technologies.
Please feel free to contact us via the link below:

Contact Us